Charles Flexner, MD, Infectious Disease, Baltimore, MD, Johns Hopkins Hospital

CharlesWilliamsFlexnerMD

Infectious Disease Baltimore, MD

Professor of Medicine, Johns Hopkins University School of Medicine; Director, AIDS Clinical Trials Unit; Deputy Director, Institute for Clinical and Translational Research

Dr. Flexner is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Flexner's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Infectious Disease, 1988 - 1989
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1985 - 1987
  • Stanford University
    Stanford UniversityResidency, Internal Medicine, 1982 - 1985
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1982

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1985 - 2022
  • CA State Medical License
    CA State Medical License 1983 - Present
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Modern HIV Therapy: Progress and Prospects 
    Virology Education B.V, Baltimore, Maryland - 11/5/2012

Other

Press Mentions

  • Johns Hopkins Experts Available in Observance of World AIDS Day
    Johns Hopkins Experts Available in Observance of World AIDS DayNovember 26th, 2019
  • Johns Hopkins Experts Available in Observance of World AIDS Day
    Johns Hopkins Experts Available in Observance of World AIDS DayNovember 26th, 2019
  • Merck Is Betting That a Mysterious New HIV Medicine Can Upend a $20 Billion Market, Using Tech Borrowed from Birth Control
    Merck Is Betting That a Mysterious New HIV Medicine Can Upend a $20 Billion Market, Using Tech Borrowed from Birth ControlMay 6th, 2019
  • Join now to see all

Grant Support

  • Johns Hopkins AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
  • ACTG A5128National Center For Research Resources2005–2007
  • ACTG A5191National Center For Research Resources2004–2007
  • ACTG A5001National Center For Research Resources2004–2007
  • ACTG 362National Center For Research Resources2004–2007
  • ACTG A5223National Center For Research Resources2006
  • Johns Hopkins Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2001–2006
  • Oral ClotrimazoleNational Center For Research Resources2004–2005
  • Interaction Of Amprenavir (Apv), Lopinavir (Lpv/R), And Efavirenz (EFV)National Center For Research Resources2004–2005
  • ACTG Screening ConsentNational Center For Research Resources2004–2005
  • ACTG 5077: Virologic StudiesNational Center For Research Resources2004–2005
  • Antiretroviral Response To Idv/Rtv Containing Regimen In Hiv-Infected SubjectsNational Center For Research Resources2004
  • ACTG A5043National Center For Research Resources2004
  • ACTG 384National Center For Research Resources2004
  • ACTG 372National Center For Research Resources2004
  • A5058s: Augmentation Of Hiv-Specific Helper And CTL Response Through TherapeuticNational Center For Research Resources2004
  • Trial Of Hydroxyurea In Combo With Antivirals In HIVNational Center For Research Resources2000–2002
  • Trial Of Efv/Nfv In Combo With Zdv/3tc/Idv In AIDSNational Center For Research Resources2000–2002
  • Protease/Nonnucleoside Transcriptase/Nucleoside HIV TherNational Center For Research Resources2000–2002
  • Pharmacokinetic Action--Protease Inhibitors &AntilipidsNational Center For Research Resources2000–2002
  • Nelfinavir Induced Diarrhea--Secretory VS NonsecretoryNational Center For Research Resources2000–2002
  • HIV Protease Inhibitor &Methadone Metabolism In HIVNational Center For Research Resources2000–2002
  • Fluconazole VS Episodic In HIV+ PTS With CandidiasisNational Center For Research Resources2000–2002
  • Blood Lymphocytes From Hiv--Coreceptor Virus IsolationNational Center For Research Resources2000–2002
  • Amprenavir In Combo With Abacavir/Efavirenz/AdefovirNational Center For Research Resources2000–2002
  • ACTG 892--Antiretroviral Therapy Effects On Lean BodyNational Center For Research Resources2000–2002
  • ACTG 365--Pharmacokinetics On Indinavir And RifabutinNational Center For Research Resources2000–2002
  • Safety And Efficacy Of Ritonavir In Combination With Nelfinavir In HIVNational Center For Research Resources1998–2002
  • Safety And Antiretroviral Activity Of Hydroxurea And DidanosineNational Center For Research Resources1998–2002
  • ACT 307--Safety/Antiretrovirl Activity Of Hydroxyurea Alone/Combination With DDINational Center For Research Resources1998–2002
  • ACTG 307 Dosing Study--Safety &Antiretroviral Activity Of HydroxyureaNational Center For Research Resources1999
  • Preliminary Antiviral Activity Study Of GEM 91 Administered To HIV+ SubjectsNational Center For Research Resources1998–1999
  • Phase I/II Multiple Dose Study Of GEM 91 Continuous IV Infusion In HIV+ PatientsNational Center For Research Resources1998–1999
  • Phase I/II Protocol To Evaluate Electroinserted Rbc-Rcd4 In HIV SubjectsNational Center For Research Resources1997–1999
  • Rifabutin And Ethambutol Effects On Clarithromycin PharmacokineticsNational Center For Research Resources1997
  • Pharmacokinetics &Preliminary Antiviral Activity Study Of GEM 91National Center For Research Resources1997

Other Languages

  • Italian

Hospital Affiliations